Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

8.3K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.3K
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

6.0K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
6.0K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

286
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
286
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

4.3K
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Occupational heavy metal exposure and endocrine-metabolic biomarkers: a retrospective analysis of 34,595 screened individuals in Türkiye.

BMC endocrine disorders·2026
Same author

Metabolic dysfunction-associated steatotic liver disease in Cushing's syndrome: prevalence, determinants, and changes after remission.

Frontiers in endocrinology·2026
Same author

Letter to the editor: Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.

Pituitary·2026
Same author

Increased prevalence of abdominal aortic aneurysm in biochemically confirmed primary aldosteronism: a new complication?

Endocrine·2026
Same author

Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.

Obesity facts·2026
Same author

Ectopic Adrenocorticotropic Hormone Syndrome Secondary to Pulmonary Neuroendocrine Tumor: Medical Stabilization Enables Serial Imaging and Localization.

AACE endocrinology and diabetes·2026

Related Experiment Video

Updated: Feb 26, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K

Vitamin D Treatment in Patients with Hashimoto's Thyroiditis may Decrease the Development of Hypothyroidism.

Bekir Ucan1, Mustafa Sahin2, Muyesser Sayki Arslan1

  • 11 Department of Endocrinology and Metabolism, Diskapi Teaching and Research Hospital, Ankara, Turkey.

International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift Fur Vitamin- Und Ernahrungsforschung. Journal International De Vitaminologie Et De Nutrition
|July 13, 2017
PubMed
Summary
This summary is machine-generated.

Vitamin D deficiency is common in Hashimoto's thyroiditis. Supplementation with vitamin D (25(OH)D3) can reduce thyroid autoantibodies and improve cardiovascular risk factors in these patients.

Keywords:
cardiovascular riskhashimoto's thyroiditisvitamin D

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K

Related Experiment Videos

Last Updated: Feb 26, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K

Area of Science:

  • Endocrinology
  • Immunology
  • Nutritional Science

Background:

  • Hashimoto's thyroiditis is an autoimmune disease affecting the thyroid gland.
  • Several studies suggest a link between vitamin D levels and Hashimoto's thyroiditis.
  • Vitamin D deficiency is prevalent in autoimmune conditions.

Purpose of the Study:

  • To assess vitamin D concentrations in patients with Hashimoto's thyroiditis.
  • To evaluate the impact of vitamin D therapy on disease progression, thyroid autoantibodies, and cardiovascular risk.
  • To compare vitamin D levels between patients and healthy controls.

Main Methods:

  • Included 75 Hashimoto's thyroiditis patients and 43 healthy controls.
  • Defined vitamin D deficiency as 25-hydroxy vitamin D (25(OH)D3) < 20 ng/mL.
  • Administered 50,000 IU of 25(OH)D3 weekly for eight weeks to deficient patients, with follow-up evaluations after two months.

Main Results:

  • Patients with Hashimoto's thyroiditis showed significantly lower vitamin D levels compared to controls (9.37±0.69 ng/mL vs 11.95±1.01 ng/mL).
  • Vitamin D therapy led to a significant decrease in thyroid autoantibodies and improved HDL cholesterol in euthyroid Hashimoto's patients.
  • Patients with Hashimoto's thyroiditis had smaller free thyroxine (fT4) and larger thyroid volumes compared to controls.

Conclusions:

  • Vitamin D deficiency is frequent in Hashimoto's thyroiditis.
  • Vitamin D replacement may slow hypothyroidism development and reduce cardiovascular risks in these patients.
  • Vitamin D monitoring and supplementation are crucial for managing Hashimoto's thyroiditis.